Compounds > wr 225448
Page last updated: 2024-12-08

wr 225448

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WR 225448: used as prophylaxis for Plasmodium yoelii infections; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID456317
CHEMBL ID289445
SCHEMBL ID4345333
MeSH IDM0129749

Synonyms (13)

Synonym
wr 225448
n4-[6-methoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]pentane-1,4-diamine
(4-amino-1-methylbutyl){6-methoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy](8-quinolyl)}amine
CHEMBL289445
SCHEMBL4345333
8-((4-amino-1-methylbutyl)amino)-6-methoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline
1,4-pentanediamine, n4-(6-methoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-
wr-225448
80065-55-0
8-(4-amino-1-methylbutylamino)-6-methoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline
n4-(6-methoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine
n~4~-{6-methoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine
DTXSID401000954
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID111784Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 5 mg/kg and activity expressed as number cures surviving 60 days1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID127128Cures in Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 0.316 mg/kg dose; Cured 2 of 21985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID117458Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) when administered at 640 mg/kg perorally; 4 Cured and in 1 Toxic1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID111779Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 10 mg/kg and activity expressed as number cures surviving 60 days1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID184594Acute toxicity administered orally was determined in 74 male rats1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID162092Minimal effective concentration inhibiting growth of Pneumocystis carinii was reported.1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID139597Evaluated for number of cures against Plasmodium berghei in mice (Mus musculus) (surviving 60 days) at dose 160 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID125814Radical curative antimalarial activity against Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 0.10 mg/kg/day over 7 days; Cured 0 of 21989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID117456Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) when administered at 5 mg/kg perorally; Inactive1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID111780Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 160 mg/kg and activity expressed as number cures surviving 60 days1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID139603Evaluated for number of cures against Plasmodium berghei in mice (Mus musculus) (surviving 60 days) at dose 80 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID111782Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 320 mg/kg and activity expressed as number cures surviving 60 days1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID199546Antimalarial activity against Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 0.316 mg/kg dose; Cured 2 of 21985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID125823Radical curative antimalarial activity against Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 1 mg/kg/day peroral dose over 7 days; Not tested1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID230860Molar primaquine index is ratio of ED50 of Compound by ED50 of primaquine in rhesus monkey1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID111786Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 640 mg/kg and activity expressed as toxic deaths on days 2-51985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID111781Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 20 mg/kg and activity expressed as number cures surviving 60 days1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID199435Antimalarial activity against Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 0.1 mg/kg; cured 0 of 11985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID199550Antimalarial activity against Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 1.0 mg/kg; cured 2 of 21985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID117465Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) when administered at 80 mg/kg perorally; Cured1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID139601Evaluated for number of cures against Plasmodium berghei in mice (Mus musculus) (surviving 60 days) at dose 5 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID111787Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 80 mg/kg and activity expressed as number cures surviving 60 days1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID127130Cures in Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 1.0 mg/kg dose; Cures 2 of 21985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID111785Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 640 mg/kg and activity expressed as number cures surviving 60 days1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID117446Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) when administered at 20 mg/kg perorally; Cured1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID117450Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) when administered at 320 mg/kg perorally; Cured1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID111783Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 40 mg/kg and activity expressed as number cures surviving 60 days1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID139598Evaluated for number of cures against Plasmodium berghei in mice (Mus musculus) (surviving 60 days) at dose 20 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID184596Acute toxicity administered orally was determined in 85 female rats1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID139600Evaluated for number of cures against Plasmodium berghei in mice (Mus musculus) (surviving 60 days) at dose 40 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID184457Acute toxicity administered intra peritoneally was determined in 85 female rats1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID127125Cures in Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 0.1 mg/kg dose; Cured 0 of 11985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID683704Antimalarial activity against Plasmodium cynomolgi M infected in rhesus monkey administered as po qd for 7 days2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID117454Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) when administered at 40 mg/kg perorally; Cured1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID125812Radical curative antimalarial activity against Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 0.0316 mg/kg/day peroral dose over 7 days; Cured 0 of 21989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID117442Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) when administered at 160 mg/kg perorally; Cured1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID139599Evaluated for number of cures against Plasmodium berghei in mice (Mus musculus) (surviving 60 days) at dose 320 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID139602Evaluated for number of cures against Plasmodium berghei in mice (Mus musculus) (surviving 60 days) at dose 640 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID139596Evaluated for number of cures against Plasmodium berghei in mice (Mus musculus) (surviving 60 days) at dose 10 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID184456Acute toxicity administered intra peritoneally was determined in 74 male rats1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID117301Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) when administered at 10 mg/kg perorally; Inactive1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
AID139758Evaluated for number of toxic deaths occurring on day 2-5 after infection with Plasmodium berghei in mice (Mus musculus) at dose 640 mg/kg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Sulfur-interrupted 8-amino side chain analogues of 4-methyl-5-[m-(trifluoromethyl)phenoxy]primaquine as potential antimalarial agents.
AID125817Radical curative antimalarial activity against Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) at 0.316 mg/kg/day peroral dose over 7 days; Cured 2 of 21989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (77.78)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.83 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		1.9610aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
dapsone
[no description available]		3.0810substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		3.1710acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
hexachlorophene
Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.		3.1710bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		3.0810aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		4.6950aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
pyrimethamine
Maloprim: contains above 2 cpds		4.6330aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		3.1710alkylamine
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		3.0810isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		3.0810aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		3.0810
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		3.1710aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
primaquine phosphate
[no description available]		1.9610
cycloguanil
cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source. cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil.		3.0810triazinesantifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
vinblastine
[no description available]		3.1710
sulfadoxine
Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.		3.0610pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
decoquinate
Decoquinate: A coccidiostat for poultry.		3.1710
dobutamine
Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.		3.1710catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
sitamaquine
[no description available]		4.0320
piritrexim
piritrexim: RN given refers to parent cpd; structure given in first source		3.0810
mibefradil
Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.		3.1710tetralinsT-type calcium channel blocker
propamidine
propamidine: structure given in first source. propamidine : A polyether that is the bis(4-guanidinophenyl) ether of propane-1,3-diol. Used (as its isethionate salt) for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis.		3.0810aromatic ether;
guanidines;
polyether		antimicrobial agent;
antiseptic drug
allicin
[no description available]		3.1710botanical anti-fungal agent;
sulfoxide		antibacterial agent
tetroxoprim
tetroxoprim: structure given in Negwer 5th ed, #6419		3.0810dimethoxybenzene
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		3.0610organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
epiroprim
epiroprim: an analog of trimethoprim with improved antimicrobial and pharmacokinetic properties; structure given in first source		3.0810
dexrazoxane
Dexrazoxane: The (+)-enantiomorph of razoxane.		3.1710razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
tebuquine
[no description available]		2.3720
grepafloxacin
grepafloxacin: structure in first source		3.1710fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		3.1710hydroxy-1,2-naphthoquinone
lopinavir
[no description available]		3.1710amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
tafenoquine
tafenoquine : A racemate comprising equimolar amounts of (R)- and (S)-tafenoquine.. N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine : An aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group.		3.4820(trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound
methotrexate
[no description available]		3.0810dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
butamidine
butamidine: RN refers to HCl; structure in first source		3.0810
wr 194965
WR 194965: structure given in first source		2.3720
wr 242511
WR 242511: RN given refers to parent cpd		3.0810
1,2-bis(5-amidino-2-benzimidazolyl)ethane
1,2-bis(5-amidino-2-benzimidazolyl)ethane: RN given refers to parent cpd		3.0810
bw 58c
[no description available]		3.0610
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		3.1710L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
dioncophylline a
dioncophylline A: derived from the tropical vine Triphyophyllum peltatum; structure given in first source. dioncophylline A : An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 7-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 4,5-dimethoxy-2-methylnaphthalen-1-yl group. It is a naphthylisoquinoline alkaloid isolated from the roots and stem barks of Triphyophyllum peltatum and exhibits antifungal, antimalarial, antineoplastic and molluscicidal activites.		3.1710biaryl;
isoquinoline alkaloid;
isoquinolines;
methoxynaphthalene;
methylnaphthalenes;
naphthalenes		antifungal agent;
antimalarial;
metabolite;
molluscicide
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		3.1710
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		3.1710macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
sesquiterpenes
[no description available]		3.0610
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		3.0610
genistein
[no description available]		3.17107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
licochalcone a
licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer		3.1710chalcones
ly 411575
[no description available]		3.1710dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor
epoxomicin
[no description available]		3.1710morpholines;
tripeptide		proteasome inhibitor
mefloquine
Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.		3.0610
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		3.1710
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		3.1710cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Plasmodium
[description not available]		04.7470
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		04.7470
Opportunistic Infections
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.		02.910
P carinii Pneumonia
[description not available]		02.910
Pneumonia, Pneumocystis
A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.		02.910